Severe Autoimmune intravascular hemolytic anemia in patients receiving Alemtuzumab for Multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022008968
Abstract: Alemtuzumab is a recombinant humanized anti-CD52 monoclonal antibody against a glycosylated, glycosylphosphatidylinositol-anchored, cell-surface protein (CD52) which is expressed at high levels on T and B lymphocytes. 1,2 It was approved by the European Medicines Agency… read more here.
Keywords: autoimmune intravascular; sclerosis; severe autoimmune; multiple sclerosis ... See more keywords